EyePoint, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jay S. Duker
- Full Time Employees
- 214
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 480 Pleasant Street Watertown MA United States 02472
- IPO Date
- Jan 27, 2005
- CIK
- 0001314102
- Website
- eyepoint.bio
- Similar Companies
- Business
- EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) develops and commercializes innovative therapeutics for serious retinal diseases using its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery; its lead product candidate DURAVYU (EYP-1901) combines vorolanib, a selective tyrosine kinase inhibitor, for VEGF-mediated conditions including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with prior Durasert formulations supporting four FDA-approved products administered to thousands of patients. Founded in 1987 and headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge, Massachusetts, the clinical-stage biopharmaceutical company targets ophthalmology markets in the US and globally through Phase 3 pivotal trials. Recently, EyePoint completed enrollment in the Phase 3 LUGANO and LUCIA trials for DURAVYU in wet AMD involving over 900 patients, with topline data from LUGANO expected mid-2026; initiated the pivotal Phase 3 DME program with COMO and CAPRI trials following FDA alignment on a non-inferiority pathway, first dosing anticipated Q1 2026; presented preclinical data at AAO 2025 showing DURAVYU reduces IL-6 mediated inflammation by over 50% via JAK-1 inhibition alongside VEGF blockade; and raised $172.5 million in an oversubscribed October 2025 public offering to fund the DME program and extend cash runway into Q4 2027.
Company News
EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)
EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus
EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript
EyePoint Announces Strategic Prioritization
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
Comparing Eyepoint Pharmaceuticals (NASDAQ:EYPT) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Here's Why You Should Add EYPT Stock to Your Portfolio Now
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Contrasting Eyepoint Pharmaceuticals (NASDAQ:EYPT) & GSK (NYSE:GSK)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
These beaten-down stocks could bounce back in January, if history is any guide
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Bristol Myers Squibb (NYSE:BMY) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) Financial Analysis